These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38908646)

  • 21. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells.
    Lee M; Park CS; Lee YR; Im SA; Song S; Lee CK
    Arch Pharm Res; 2014; 37(9):1234-40. PubMed ID: 24748512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment.
    Sakakura K; Takahashi H; Kaira K; Toyoda M; Murata T; Ohnishi H; Oyama T; Chikamatsu K
    Lab Invest; 2016 Sep; 96(9):994-1003. PubMed ID: 27322955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human inflammatory dendritic cells in malignant pleural effusions induce Th1 cell differentiation.
    Gu FF; Wu JJ; Liu YY; Hu Y; Liang JY; Zhang K; Li M; Wang Y; Zhang YA; Liu L
    Cancer Immunol Immunother; 2020 May; 69(5):779-788. PubMed ID: 32052078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer.
    Lu J; Li J; Lin Z; Li H; Lou L; Ding W; Ouyang S; Wu Y; Wen Y; Chen X; Yue P; Wang Y; Liu P; Lu J; Zhang J; Feng W; Zhang X
    Cancer Lett; 2023 Jun; 564():216205. PubMed ID: 37146936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer.
    Zhou J; Xu Y; Wang G; Mei T; Yang H; Liu Y
    Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35552764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cationic lipid-assisted nanoparticles for simultaneous delivery of CD47 siRNA and R848 to promote antitumor immune responses.
    Li S; Chen Y; Ma R; Du Y; Han B
    Front Pharmacol; 2023; 14():1142374. PubMed ID: 37063284
    [No Abstract]   [Full Text] [Related]  

  • 29. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
    Kauder SE; Kuo TC; Harrabi O; Chen A; Sangalang E; Doyle L; Rocha SS; Bollini S; Han B; Sim J; Pons J; Wan HI
    PLoS One; 2018; 13(8):e0201832. PubMed ID: 30133535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extracellular Matrix Protein Tenascin C Increases Phagocytosis Mediated by CD47 Loss of Function in Glioblastoma.
    Ma D; Liu S; Lal B; Wei S; Wang S; Zhan D; Zhang H; Lee RS; Gao P; Lopez-Bertoni H; Ying M; Li JJ; Laterra J; Wilson MA; Xia S
    Cancer Res; 2019 May; 79(10):2697-2708. PubMed ID: 30898840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
    Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
    J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer.
    Hong X; Dong T; Hu J; Yi T; Li W; Zhang Z; Lin S; Niu W
    Int J Colorectal Dis; 2013 Jan; 28(1):25-33. PubMed ID: 22777000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
    Liu Z; Xie Y; Xiong Y; Liu S; Qiu C; Zhu Z; Mao H; Yu M; Wang X
    Cancer Lett; 2020 Jan; 469():173-185. PubMed ID: 31629935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Theranostic nanoparticles ZIF-8@ICG for pH/NIR-responsive drug-release and NIR-guided chemo-phototherapy against non-small-cell lung cancer.
    Lu K; Pan X; Zheng J; Cheng D; Zheng L; Zhang X
    J Mater Sci Mater Med; 2024 Jun; 35(1):32. PubMed ID: 38896160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.
    Kim WS; Kim H; Kwon KW; Im SH; Lee BR; Ha SJ; Shin SJ
    Oncotarget; 2016 Jun; 7(23):33765-82. PubMed ID: 27172902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.
    Weiskopf K; Jahchan NS; Schnorr PJ; Cristea S; Ring AM; Maute RL; Volkmer AK; Volkmer JP; Liu J; Lim JS; Yang D; Seitz G; Nguyen T; Wu D; Jude K; Guerston H; Barkal A; Trapani F; George J; Poirier JT; Gardner EE; Miles LA; de Stanchina E; Lofgren SM; Vogel H; Winslow MM; Dive C; Thomas RK; Rudin CM; van de Rijn M; Majeti R; Garcia KC; Weissman IL; Sage J
    J Clin Invest; 2016 Jul; 126(7):2610-20. PubMed ID: 27294525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
    Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
    J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma.
    Xu B; Tian L; Chen J; Wang J; Ma R; Dong W; Li A; Zhang J; Antonio Chiocca E; Kaur B; Feng M; Caligiuri MA; Yu J
    Nat Commun; 2021 Oct; 12(1):5908. PubMed ID: 34625564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.
    Pham TN; Hong CY; Min JJ; Rhee JH; Nguyen TA; Park BC; Yang DH; Park YK; Kim HR; Chung IJ; Kim HJ; Lee JJ
    Exp Mol Med; 2010 Jun; 42(6):407-19. PubMed ID: 20386085
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Bamodu OA; Kuo KT; Wang CH; Huang WC; Wu ATH; Tsai JT; Lee KY; Yeh CT; Wang LS
    Nutrients; 2019 Sep; 11(10):. PubMed ID: 31547048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.